Sorrento Therapeutics, Inc.
Case Number:
4:23-bk-90085
Court:
Nature of Suit:
Firms
- Husch Blackwell
- Martin P. Eramo APC
- Gray Reed
- Chapman & Cutler
- Andrews Myers
- Christian Levine Law Group
- Finch Thornton
- Coats Rose
- Pashman Stein
- Norton Rose
- McGuireWoods
- Maynard Nexsen
- Buchalter APC
- Warshaw Burstein
- Rusty Hardin & Associates
- K&L Gates
- Quinn Emanuel
- Locke Lord
- Pillsbury Winthrop
- ASK LLP
- Cowles & Thompson
- Harvest LLP
- Gibbs Giden
- Munsch Hardt
- Sheppard Mullin
- Kean Miller
- Tran Singh
- Franklin Soto Leeds
- Probus Law Firm
- Kane Russell
- Baker Botts
- Thompson Coburn
- Doyle Restrepo
- WilmerHale
- Porter Hedges
- Troutman Pepper
- Davis Graham
- Duane Morris
- Tucker Arensberg
- Sidley Austin
- Ohashi & Horn
- Ferguson Braswell
- DLA Piper
- Katten Muchin
- Miller Nash LLP
- Clark Hill
- Reed Smith
- Glenn Agre
- Ross Smith & Binford
- Greenberg Traurig
- Paul Hastings
- Shook Hardy
- Jones Walker
- Bressler Amery
- Jones Day
- Jackson Walker LLP
- Latham & Watkins
- Milbank LLP
Companies
- The Scripps Research Institute
- Cetera Financial Institutions
- HSBC Holdings PLC
- PCI Pharma Services
- The Charles Schwab Corp.
- Sorrento Therapeutics Inc.
- Interactive Brokers Group Inc.
- BMO Harris Bank NA
- Barclays PLC
- Apex Clearing Corporation
- Bank of America Corp.
- FMR LLC
- Moelis & Co.
- Raymond James Financial Inc.
- Mayo Foundation for Medical Education and Research
- Edward D. Jones & Co. LP
- Wedbush Securities Inc.
- The Goldman Sachs Group Inc.
- Phillip Capital Inc.
- TR Capital Management LLC
- Precision for Medicine Holdings Inc.
- Protiviti Inc.
- NantWorks LLC
- FTI Consulting Inc.
- JPMorgan Chase & Co.
- ABN AMRO Bank NV
- Stretto Inc.
- Fortis Advisors LLC
- BMO Capital Markets Corp.
- Oracle Corp.
- Emas Pharma Ltd.
- LPL Financial Holdings Inc.
- Pershing Group LLC
- New England Biolabs Inc.
- Robert Half Inc.
- Prospect Medical Holdings Inc.
- Charles River Laboratories International Inc.
- The Bank of New York Mellon Corp.
- Morgan Stanley
- Kilroy Realty Corporation
- UBS Group AG
Sectors & Industries:
-
August 12, 2024
Sorrento Shareholders' Fee Objection Too Late, Judge Says
A Texas bankruptcy judge on Monday found a group of Sorrento Therapeutics shareholders objected too late to proposed fee payments to Jackson Walker LLP for its work on Sorrento's Chapter 11 case, denying them the opportunity to present evidence at a fee hearing next month.
-
July 11, 2024
Sorrento Investors Rip Atty Fee Requests Over 'Scant' Results
A group of Sorrento Therapeutics Inc. shareholders has asked a Texas bankruptcy judge to reject $50 million in fee applications by lawyers for the drug developer, charging that the Chapter 11 case has been a "disaster for all stakeholders other than for professionals."
-
May 23, 2024
Ex-Judge Pushed False Narrative On Atty Romance, Firm Says
U.S. Bankruptcy Judge David R. Jones of Texas, who resigned last year after his secret relationship with a Jackson Walker LLP partner was revealed, attempted to head off rumors about the relationship by asking the firm to file a false, partial disclosure in 2022, the firm alleged.
-
March 26, 2024
Sorrento Gets Green Light To Delay $21M Ch. 11 Sale
Drug developer Sorrento Therapeutics can push the close of its $20.9 million asset sale from Thursday to April 1, a Texas bankruptcy judge ruled Tuesday, after attorneys for the debtor said they reached new terms for the deal that will help fund the company as it winds down under its Chapter 11 plan.
-
March 12, 2024
Sorrento Ch. 11 Will Stay In Texas
A Texas bankruptcy judge Tuesday denied requests to transfer the Chapter 11 case of drug developer Sorrento Therapeutics Inc. out of the Lone Star State for having insufficient ties to the venue.
-
March 08, 2024
Sorrento Gets OK For $2M Ch. 11 Funding Infusion, Asset Sale
A Texas bankruptcy judge on Friday approved drug developer Sorrento Therapeutics Inc.'s bid for an asset sale and $2 million in funds to fuel its Chapter 11 case, saying they represented the only option outside of a transition to Chapter 7.
-
March 04, 2024
Sorrento Creditors Fight To Keep Ch. 11 In Texas
Creditors for drug developer Sorrento Therapeutics Inc. have asked a Texas bankruptcy judge to keep the company's Chapter 11 case in the Lone Star State, saying the U.S. trustee's bid to move it comes too late and wouldn't help those hoping for recoveries.
-
February 27, 2024
Latham, Jackson Walker Avoid Sanctions Over Sorrento Venue
A Texas bankruptcy judge declined to level sanctions against Latham & Watkins LLP and Jackson Walker LLP for trying to establish Texas jurisdiction for California-based Sorrento Therapeutics Inc. in its Chapter 11 bankruptcy, finding that their conduct did not amount to bankruptcy fraud.
-
February 22, 2024
Sorrento Says US Trustee's Protest Of Texas Venue Off Base
Sorrento Therapeutics Inc. told a Texas bankruptcy court the company's choice to bring a Chapter 11 in the Lone Star State was sound, so the court should ignore a call from the U.S. Trustee's Office to trash or relocate the case.
-
February 20, 2024
US Trustee Wants Sorrento Ch. 11 Tossed Or Relocated
The U.S. Trustee's Office has moved to have Sorrento Therapeutics' Chapter 11 case dismissed, alleging the biopharmaceutical company manufactured a venue in Texas bankruptcy court, even as the debtor asked for court approval to sell off its assets to its CEO under a revised reorganization plan.